Fig. 7: Changes in the tumor microenvironment after CAR-T + NVs@cGAMP treatment.
a To assess the proliferation of CAR-T cells in different treatment groups, bioluminescence intensity was measured by IVIS at different time points after the injection of CAR-T cells expressing luciferase. b, c Representative flow cytometry plots and statistical analysis of (b) CD8+ T cells and CD4+ T cells and (c) infiltrating granzyme B-expressing CD8+ T cells within the TME across various treatment groups (n = 4 mice). d, e Representative flow cytometry plots and statistical analysis of T cell exhaustion markers (PD-1, TIM-3, LAG-3, TIGIT) on CAR-T within the TME across various treatment groups (n = 4 mice). f Representative flow cytometry plots and statistical analysis of Th1, Th2 and Th17 within the TME across various treatment groups (n = 4 mice). g Representative flow cytometry plots and statistical analysis of M1-type and M2-type macrophages within the TME across various treatment groups (n = 4 mice). h Representative flow cytometry plots and statistical analysis of Tregs, MDSCs and mature DCs within the TME across various treatment groups (n = 4 mice). i Representative flow cytometry plots and statistical analysis of naïve T cells, central memory T cells (TCM), and effector memory T cells (TEM) within the CAR-T cell population in the TME across different treatment groups (n = 4 mice). All the data are expressed as mean ± S.D. The p values were determined by one-way ANOVA with Tukey’s post-test for (b, c) and (e–i). Source data underlying b, c, e–i are provided as a Source Data file.
